COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: “Death” and “Recovery”. Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O₂) requirements 10.4 l/min. At baseline, all patients had multiple biological abnormalities (lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer and liver enzymes). 24 patients (70.5%) recovered after TCZ therapy and 10 died (29.5%). Deceased subjects differed from patients in whom treatment was effective with regard to more pronounced lymphopenia (0.6 vs 1.0 G/l; p = 0.037), lower platelet number (156 vs 314 G/l; p = 0.0001), lower fibrinogen serum level (0.6 vs 1.0 G/l; p = 0.03), higher aspartate-amino-transferase (108 vs 57 UI/l; p = 0.05) and greater O₂ requirements (11 vs 8 l/min; p = 0.003).

患有ARDS的COVID-19患者（n = 34）接受了tocilizumab（TCZ）治疗。结果分为两类：“死亡”和“恢复”。研究了死亡率的预测因素。平均年龄为75.3，平均氧气（O ₂）需求为10.4 l / min。在基线时，所有患者均具有多种生物学异常（淋巴细胞减少，CRP升高，铁蛋白，纤维蛋白原，D-二聚体和肝酶）。TCZ治疗后恢复了24例患者（70.5％），死亡10例（29.5％）。死者与治疗有效的患者有所不同，包括更明显的淋巴细胞减少症（0.6 vs 1.0 G / l ； p  = 0.037），较低的血小板数量（156 vs 314 G / l；p  = 0.0001），较低的纤维蛋白原血清水平（ 0.6和1.0 G / l ; p = 0.03），更高的天冬氨酸-氨基转移酶（108 vs 57 UI / l；p  = 0.05）和更高的O ₂需求量（11 vs 8 l / min；p  = 0.003）。